How much does the latest box of Revumenib-Revuforj cost?

Revumenib (Revumenib)-Revuforj is an innovative anti-leukemia drug targeting specific molecular targets. Its main function is to inhibit the oncogenic signaling pathway related to lysine methyltransferase 2A (KMT2A). KMT2A translocation is a common genetic abnormality in acute leukemia, which promotes leukemia cell proliferation and survival through abnormal gene rearrangement. Rivimenib precisely intervenes in this pathway to inhibit leukemia cell proliferation and improve patient prognosis. This precise targeting mechanism makes revimenib more selective and potentially safer than traditional chemotherapy drugs.

Clinical studies have shown that Revimenib has significant therapeutic potential for patients with relapsed or refractory acute leukemia (including AML and ALL) carryingKMT2A translocation, including adults and children over 1 year old. In overseas markets, Revimenib is provided in the form of oral tablets, with main specifications including 110 mg 30 tablets and 160 mg 30 tablets, allowing patients to adjust the dosage according to their weight and clinical plan. Due to high research and development costs and a limited target group of patients, Rivimenib is very expensive. The latest price of the US version of the original drug may reach more than 200,000 yuan per box, and the price will be affected by exchange rate fluctuations.

At present, Revimenib has not yet been launched in China, and domestic patients can only obtain the US version of the original drug through overseas channels. This means that there are certain thresholds in terms of cost and access to drugs, and they need to rely on international medical or clinical research projects. Despite its high price, Revimenib offers a new treatment hope for patients with relapsed or refractory leukemia who have failed traditional therapies. Clinicians usually recommend medication under guidance while closely monitoring hematological indicators and liver and kidney functions to ensure safety.

Reference materials:https://www.drugs.com/monograph/revumenib.html